Roche inks $774M pact

Invitrogen Applera's Applied Biosystems $6.7B merger

Invitrogen has agreed to acquire all of the shares of Applera's Applied Biosystems in a $6.7 billion cash and stock deal. The companies are two of the biggest suppliers to the drug development business.

Roche ThromboGenics and BioInven$774M deal

In the deal, ThromboGenics gets a whopping $77.4 million upfront payment from Roche, with close to $700 million in milestones that will be split 60/40 between ThromboGenics and BioInvent.

Boehringer IngelheimActimis Pharmaceuticals$515M buyout

Boehringer is buying Actimis Pharmaceuticals, which is developing asthma and allergy drugs.

Kyowa HakkoAlnylam Pharmaceuticals $93M development pact

Cambridge, MA-based Alnylam will develop an Respiratory Syncytial Virus therapy for Asian markets.

Parexel ClinPhone$182M buyout

CRO Parexel has made a $182 million bid for U.K.-based ClinPhone, but it may be facing competition from Quintiles, the world's largest private CRO.

Stiefel Laboratories Barrier Therapeutics$148M buyout

Barrier Therapeutics is a developer of dermatology products.

Roche inks $774M pact

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.